INSULET CORPORATION (NASDAQ:PODD) Files An 8-K Results of Operations and Financial Condition
INSULET CORP Exhibit
EX-99.1 2 a51945444ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Insulet Reports Fourth Quarter 2018 Revenue of $164.9 Million,…
To view the full exhibit click
About INSULET CORPORATION (NASDAQ:PODD)
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). The Company purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The Company purchases OmniPods pursuant to its agreement with Flextronics. The OmniPod System is available in Europe, Canada and Israel.